Home › Research › Lewy body dementia
Research progress on the role of oxidative stress in the pathogenesis of vascular dementia and its treatment
Hongxiao Lv, Yutong Liu, Xinyu Yang, Xi-Qi Xu, Junwei Zhou, Wentao Yu. Journal of Stroke and Cerebrovascular Diseases, 2025-10-18
Topic: Risk, prevention and care in population studies
Oxidative stress is deeply involved in multiple pathological processes of VaD. Its root cause lies in chronic cerebral hypoperfusion (CCH), which leads to mitochondrial dysfunction and excessive ROS production. Such oxidative damage exacerbates blood-brain barrier (BBB) disruption, neuroinflammation, and neuronal apoptosis, ultimately resulting in cognitive decline. Key molecular mechanisms include the activation of NADPH oxidase, impairment of the Nrf2 antioxidant pathway, and dysregulation of SIRT1. Therapeutic strategies have evolved from traditional antioxidants (e.g., α-lipoic acid) to novel approaches, including targeting the Nrf2/HO-1 pathway (e.g., using saffron-rich GJ-4 extract), regulating mitochondrial function, utilizing natural compounds (e.g., resveratrol acting via SIRT1 activation), and non-pharmacological interventions such as acupuncture. These strategies alleviate oxidative stress through multi-target mechanisms and have demonstrated significant efficacy. The central role of oxidative stress in VaD provides new targets for treatment, but a shift from single-target antioxidant therapy to multi-level intervention is required. Future research should focus on developing targeted antioxidant therapies, exploring combination treatment regimens, and validating biomarkers applicable for early detection and therapeutic efficacy assessment.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lv, H., Liu, Y., Yang, X., Xu, X.-Q., Zhou, J., & Yu, W. (2025). Research progress on the role of oxidative stress in the pathogenesis of vascular dementia and its treatment. Journal of Stroke and Cerebrovascular Diseases. https://doi.org/10.1016/j.jstrokecerebrovasdis.2025.108475
Vancouver
Lv H, Liu Y, Yang X, Xu X.-Q, Zhou J, Yu W. Research progress on the role of oxidative stress in the pathogenesis of vascular dementia and its treatment. Journal of Stroke and Cerebrovascular Diseases. 2025. doi:10.1016/j.jstrokecerebrovasdis.2025.108475. PMID: 41110565.
BibTeX
@article{lv2025-41110565,
author = {Lv, Hongxiao and Liu, Yutong and Yang, Xinyu and Xu, Xi-Qi and Zhou, Junwei and Yu, Wentao},
title = {{Research progress on the role of oxidative stress in the pathogenesis of vascular dementia and its treatment}},
journal = {Journal of Stroke and Cerebrovascular Diseases},
year = {2025},
doi = {10.1016/j.jstrokecerebrovasdis.2025.108475},
pmid = {41110565},
url = {https://doi.org/10.1016/j.jstrokecerebrovasdis.2025.108475}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Oxidative stress is deeply involved in multiple pathological processes of VaD.
- Its root cause lies in chronic cerebral hypoperfusion (CCH), which leads to mitochondrial dysfunction and excessive ROS production.
- Such oxidative damage exacerbates blood-brain barrier (BBB) disruption, neuroinflammation, and neuronal apoptosis, ultimately resulting in cognitive decline.
- Key molecular mechanisms include the activation of NADPH oxidase, impairment of the Nrf2 antioxidant pathway, and dysregulation of SIRT1.
- Therapeutic strategies have evolved from traditional antioxidants (e.g., α-lipoic acid) to novel approaches, including targeting the Nrf2/HO-1 pathway (e.g., using saffron-rich GJ-4 extract), regulating mitochondrial function, utilizing natural compounds (e.g., resveratrol acting via SIRT1 activation), and non-pharmacological interventions such as acupuncture.
Why it matters
This review describes how oxidative stress contributes to vascular dementia through mechanisms including mitochondrial dysfunction and impaired antioxidant pathways, and discusses therapeutic strategies from traditional antioxidants to newer approaches. It provides a theoretical framework for treatment but does not report results from a clinical trial.
Study details
- Evidence strengthLow
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Stroke and Cerebrovascular Diseases) |
| Journal's citation record | 1 / 4 | Journal of Stroke and Cerebrovascular Diseases: journal h-index 104 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 4.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Wentao Yu: h-index 5 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Capital Medical University: institution h-index 643 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41110565) |
| Free to read | 2 / 2 | Free to read |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.jstrokecerebrovasdis.2025.108475
- PubMed: 41110565
- Original source →
- Free full text: Journal of Stroke and Cerebrovascular Diseases →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Lewy body dementia
Also tagged “small”
900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.